Patents
Literature
4 results about "Barbiturate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A barbiturate is a drug that acts as a central nervous system depressant, and can therefore produce a wide range of effects, from mild sedation to death. Barbiturates are effective as anxiolytics, hypnotics, and anticonvulsants, but have physical and psychological addiction potential as well as overdose potential among other possible adverse effects. They have largely been replaced by benzodiazepines and nonbenzodiazepines ("Z-drugs") in routine medical practice, particularly in the treatment of anxiety and insomnia, due to the significantly lower risk of addiction and overdose and the lack of an antidote for barbiturate overdose. Despite this, barbiturates are still in use for various purposes: in general anesthesia, epilepsy, treatment of acute migraines or cluster headaches, euthanasia, capital punishment, and assisted suicide.
Specific arylidene barbiturate derivative molecules for use as drug candidates in cancer treatment
PendingEP4618960A4Organic chemistryKetone active ingredientsPharmaceutical drugPharmaceutical Substances
The invention relates to the compound shown in Formula I, II, III and IV or pharmaceutically acceptable salt, solvent, hydrate, hydrate salt, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer thereof effective in the treatment of cancer.
Owner:T C ISTANBUL MEDIPOL UNIVERSITESI +1
Transcranial focused ultrasound for hypertension treatment
A minimally invasive method for lowering hypertension using focused ultrasound is provided. Following injection of ultrasound-responsive nanodroplets containing a therapeutic agent (e.g., a barbiturate), focused ultrasound is delivered to norepinephrine-producing regions, such as the periaqueductal gray area, resulting in localized release of the therapeutic payload from the nanodroplets, achieving therapeutic blood pressure reduction. Acoustic emissions from the evaporating droplets can be used to infer one or more therapeutic parameters, for example, based on pre-established correlations. For example, changes in plasma hormone content and / or blood pressure can be inferred, thereby providing a means for real-time treatment monitoring. An exemplary method of the present invention can be used to achieve blood pressure reduction in subjects exhibiting drug-resistant hypertension.
Owner:SUNNYBROOK RES INST
5-[2,7-diazaspiro[3,5]nonane-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives used as MMP9 inhibitors for the treatment of dry eye disease
PendingCN122138962AOrganic active ingredientsSenses disorderOcular surface diseasePharmaceutical medicine
This invention relates to spirocyclic barbiturates of general formula (I) or pharmaceutically acceptable salts thereof as MMP9 inhibitors for the treatment of ocular surface diseases, such as, for example, dry eye disease.
![5-[2,7-diazaspiro[3,5]nonane-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives used as MMP9 inhibitors for the treatment of dry eye disease](https://images-eureka.patsnap.com/patent_img/c0ad7e4f-ba79-490d-b4c6-aea24f6dbafb/CN122138962A.png "5-[2,7-diazaspiro[3,5]nonane-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives used as MMP9 inhibitors for the treatment of dry eye disease")
Owner:F HOFFMANN LA ROCHE & CO AG
Methods for the treatment of hypertension via transcranial-focused-ultrasound
A minimally invasive method for the reduction of hypertension is provided using focused ultrasound. After injection of ultrasound-responsive nanodroplets loaded with a therapeutic agent (e.g. barbiturates), focused ultrasound is delivered to a norepinephrine-producing region, such as the periaqueductal gray region, thereby locally releasing the therapeutic agent payload from the nanodroplets and achieving a therapeutic reduction in blood pressure. Acoustic emissions from vaporizing droplets may be employed, for example, to infer one or more therapeutic parameters based on a pre-established correlation. For example, plasma hormone content and / or the change in blood pressure may be inferred, thereby providing a means of real-time treatment monitoring. The present example methods may be employed to achieve a reduction in blood pressure for subjects exhibiting drug-resistant hypertension.
Owner:SUNNYBROOK RES INST